Navigation Links
Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
Date:8/4/2009

cial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; l
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Woodstock, Vt. (PRWEB) August 28, 2014 ... microbiology testing around the world is available from ... industrial diagnostics companies. “ Industrial Microbiology Market Review, ... the Industrial Market ” (IMMR—4) tracks and compares ... in in North America, Europe and Asia, and ...
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
(Date:8/27/2014)... 2014 In 2013, Lawrence ... Livermore National Security LLC (LLNS), was awarded ... a state-of-the-art laser system for the European Union's ... construction in the Czech Republic. , When commissioned ... called the " High repetition-rate Advanced Petawatt Laser ...
(Date:8/27/2014)... 2014 The Global and China Trifluoroacetic ... the current state of the Trifluoroacetic Acid industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... Food and Drug Administration (FDA) regarding a Special Protocol ...
... - OncoGenex Pharmaceuticals (NASDAQ: OGXI ) announced today ... Thursday, August 6, 2009. OncoGenex will host a conference call ... discuss quarterly results. , The webcast can be accessed on ... www.oncogenex.com . Alternatively, you may access the live conference ...
... The years of ... big breakthrough in the search for a viable alternative feedstock for biodiesel in combination with ... happy to announce the much awaited commercial release of Couple oil crop cultivation (COC) technology. ... (PRWEB) August 3, 2009 ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 4Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3
(Date:8/28/2014)... mould in homes could pose a significant health risk to ... the Journal of Allergy and Clinical Immunology . , ... different countries, the research has found that the presence of ... asthma sufferers, as well as increasing the likelihood of developing ... team at the University of Exeter Medical School and is ...
(Date:8/28/2014)... crop-producing countries will be fully saturated with pests by ... according to a new study led by the University ... already be found in around half the countries that ... its current rate, scientists fear that a significant proportion ... within the next 30 years. , Crop pests include ...
(Date:8/27/2014)... 2014. Using functional near infrared spectroscopy (fNIRS), Kessler ... between people with multiple sclerosis (MS) and healthy ... which brain activation was studied using fNIRS while ... and cognition using functional near infrared spectroscopy (fNIRS) ... 11 by Brain Imaging and Behavior . ...
Breaking Biology News(10 mins):Indoor mold poses health risk to asthma sufferers 2New study charts the global invasion of crop pests 2Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2
... of scientists who set out to study sex pheromones in a ... a stage in the worms, life cycle, the long-lived dauer larva. ... on July 23, represent the first time that reproduction and lifespan ... scientists once focused on DNA and proteins as the major players ...
... heart grow fonder, but endurance exercise seems to make it ... of Medicine in St. Louis, older people who did endurance ... much younger hearts. The researchers also showed that by one ... , "We know that the heart deteriorates as people ...
... publication of the first issue of , Energy & ... scientific community. Free for all to read online, ... fuel cells, hydrogen storage, thermochemical biofuel production, sustainable energy, ... submitted work of the highest quality, knowing that they ...
Cached Biology News:Sex and lifespan linked in worms 2Exercise could be the heart's fountain of youth 2Exercise could be the heart's fountain of youth 3
384 Cluster Tube Racks...
...
Request Info...
... Partially purified chicken intestinal cytoplasmic ... D receptor (VDR) from human, rat, ... tissues. This antibody does not ... MA1-710 detects both the occupied ...
Biology Products: